{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:56:17Z","timestamp":1790290577274,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.03.022","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T02:46:08Z","timestamp":1490064368000},"page":"5981-5989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?"],"prefix":"10.1016","volume":"35","author":[{"given":"Richard W.","family":"Titball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary N.","family":"Burtnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Bancroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.03.022_b0005","doi-asserted-by":"crossref","first-page":"14246","DOI":"10.1073\/pnas.0403306101","article-title":"Structural flexibility in the Burkholderia mallei genome","volume":"101","author":"Nierman","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.03.022_b0010","article-title":"Melioidosis: a clinical overview","volume":"9","author":"Limmathurotsakul","year":"2011","journal-title":"Br Med Bull"},{"key":"10.1016\/j.vaccine.2017.03.022_b0015","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1204699","article-title":"Melioidosis","volume":"367","author":"Wiersinga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.03.022_b0020","series-title":"Biohazard: the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it","author":"Alibek","year":"1999"},{"key":"10.1016\/j.vaccine.2017.03.022_b0025","series-title":"SIPRI chemical and biological warfare studies 18 biological and toxin weapons: research, development and use from the middle ages to 1945","first-page":"215","article-title":"US biological warfare planning and preparedness: the dilemmas of policy","author":"Moon","year":"1999"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.03.022_b0030","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0035-9203(08)70026-9","article-title":"Burkholderia pseudomallei: animal models of infection","volume":"102","author":"Titball","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.022_b0035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/infdis\/124.6.598","article-title":"The pseudomallei group: a review","volume":"124","author":"Howe","year":"1971","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0040","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4269\/ajtmh.2010.10-0038","article-title":"Increasing incidence of human melioidosis in Northeast Thailand","volume":"82","author":"Limmathurotsakul","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.022_b0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1128\/CMR.18.2.383-416.2005","article-title":"Melioidosis: epidemiology, pathophysiology and management","volume":"18","author":"Cheng","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.03.022_b0050","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1086\/520223","article-title":"Risk factors for melioidosis and bacteremic melioidosis","volume":"29","author":"Suputtamongkol","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0055","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat Microbiol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.03.022_b0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0035-9203(08)70002-6","article-title":"The global distribution of Burkholderia pseudomallei and melioidosis: an update","volume":"102","author":"Currie","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.022_b0065","doi-asserted-by":"crossref","first-page":"e0132032","DOI":"10.1371\/journal.pone.0132032","article-title":"Recombinant Salmonella expressing Burkholderia mallei LPS O antigen provides protection in a murine model of melioidosis and glanders","volume":"10","author":"Moustafa","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.022_b0070","doi-asserted-by":"crossref","first-page":"e0003863","DOI":"10.1371\/journal.pntd.0003863","article-title":"Characterization of the Burkholderia mallei tonb mutant and its potential as a backbone strain for vaccine development","volume":"9","author":"Mott","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0075","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/CVI.00533-10","article-title":"In vitro and in vivo studies on monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei","volume":"18","author":"Zhang","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0080","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1021\/pr1012398","article-title":"Outer membrane proteome of Burkholderia pseudomallei and Burkholderia mallei from diverse growth conditions","volume":"10","author":"Schell","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1016\/j.vaccine.2017.03.022_b0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.provac.2010.03.013","article-title":"Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge","volume":"2","author":"Whitlock","year":"2010","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0090","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1016\/j.vaccine.2009.05.040","article-title":"Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders","volume":"27","author":"Sarkar-Tyson","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.03.022_b0095","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0035-9203(08)70016-6","article-title":"Sero-characterization of lipopolysaccharide from Burkholderia thailandensis","volume":"102","author":"Qazi","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.022_b0100","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1128\/IAI.05044-11","article-title":"The Burkholderia pseudomallei Deltaasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice","volume":"79","author":"Norris","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0105","first-page":"123","article-title":"Construction and characterization of an unmarked aroC deletion mutant of Burkholderia pseudomallei strain A2","volume":"40","author":"Srilunchang","year":"2009","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2017.03.022_b0110","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0035-9203(08)70022-1","article-title":"Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle","volume":"102","author":"Breitbach","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.03.022_b0115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/IAI.01102-15","article-title":"Characterization of new virulence factors involved in the intracellular growth and survival of Burkholderia pseudomallei","volume":"84","author":"Moule","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0120","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/IAI.00328-16","article-title":"Burkholderia mallei clh001 attenuated vaccine strain is immunogenic and protects against acute respiratory glanders","volume":"84","author":"Hatcher","year":"2016","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0125","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1128\/IAI.00178-12","article-title":"Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity","volume":"80","author":"Muller","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0130","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.micinf.2005.04.013","article-title":"A model of immunity to Burkholderia pseudomallei: unique responses following immunization and acute lethal infection","volume":"7","author":"Ulett","year":"2005","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2017.03.022_b0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1099\/0022-1317-51-7-539","article-title":"Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis","volume":"51","author":"Atkins","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0140","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1128\/CVI.00113-13","article-title":"Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule","volume":"20","author":"Scott","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0145","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1128\/IAI.00915-13","article-title":"Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine","volume":"81","author":"Silva","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0150","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/IAI.01313-09","article-title":"A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists","volume":"78","author":"Propst","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fcimb.2013.00010","article-title":"Development of Burkholderia mallei and pseudomallei vaccines","volume":"3","author":"Silva","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0160","doi-asserted-by":"crossref","first-page":"e1488","DOI":"10.1371\/journal.pntd.0001488","article-title":"Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes","volume":"6","author":"Peacock","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0165","doi-asserted-by":"crossref","DOI":"10.3201\/eid2106.141480","article-title":"Consensus on the development of vaccines against naturally acquired melioidosis","volume":"21","author":"Limmathurotsakul","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0170","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1016\/j.vaccine.2014.08.035","article-title":"Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge","volume":"32","author":"Puangpetch","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2172-9-55","article-title":"Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei","volume":"9","author":"Whitlock","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0180","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1128\/IAI.00834-06","article-title":"Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis","volume":"74","author":"Geurtsen","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0185","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1016\/j.vaccine.2011.08.058","article-title":"A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection","volume":"29","author":"Nieves","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0190","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CVI.00119-14","article-title":"A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis","volume":"21","author":"Nieves","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.provac.2014.07.007","article-title":"Evaluation of a Burkholderia pseudomallei outer membrane vesicle vaccine in nonhuman primates","volume":"8","author":"Petersen","year":"2014","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0200","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/IAI.73.2.1106-1115.2005","article-title":"The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition","volume":"73","author":"Reckseidler-Zenteno","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0205","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1046\/j.1365-2958.1998.01139.x","article-title":"The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence","volume":"30","author":"DeShazer","year":"1998","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0210","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1099\/mic.0.27146-0","article-title":"Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis","volume":"150","author":"Stevens","year":"2004","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2017.03.022_b0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2958.2004.04528.x","article-title":"Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei","volume":"56","author":"Stevens","year":"2005","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0220","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/IAI.01218-10","article-title":"The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei","volume":"79","author":"Burtnick","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0225","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/IAI.01240-06","article-title":"Development of signature tagged mutagenesis in Burkholderia pseudomallei to identify mutants important in survival, attenuation and pathogenesis","volume":"75","author":"Cuccui","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0230","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jiq142","article-title":"Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis","volume":"203","author":"Suwannasaen","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0235","doi-asserted-by":"crossref","first-page":"13499","DOI":"10.1073\/pnas.0812080106","article-title":"A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens","volume":"106","author":"Felgner","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.03.022_b0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fmicb.2011.00227","article-title":"Protective antigens against glanders identified by expression library immunization","volume":"2","author":"Whitlock","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0245","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.vaccine.2016.02.038","article-title":"Immunisation with proteins expressed during chronic murine melioidosis provides enhanced protection against disease","volume":"34","author":"Champion","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0250","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.4049\/jimmunol.1402862","article-title":"T cell immunity to the alkyl hydroperoxide reductase of Burkholderia pseudomallei: a correlate of disease outcome in acute melioidosis","volume":"194","author":"Reynolds","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0255","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/eji.201040881","article-title":"CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis","volume":"41","author":"Chu","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0260","doi-asserted-by":"crossref","DOI":"10.4172\/1745-7580.1000043","article-title":"Immunogenic consensus sequence t helper epitopes for a pan-Burkholderia biodefense vaccine","volume":"7","author":"De Groot","year":"2011","journal-title":"Immunome Res"},{"key":"10.1016\/j.vaccine.2017.03.022_b0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jtbi.2016.04.009","article-title":"Identification of CD4+ T-cell epitope and investigation of HLA distribution for the immunogenic proteins of Burkholderia pseudomallei using in silico approaches - A key vaccine development strategy for melioidosis","volume":"400","author":"Swetha","year":"2016","journal-title":"J Theor Biol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0270","doi-asserted-by":"crossref","first-page":"e0003917","DOI":"10.1371\/journal.pntd.0003917","article-title":"Sequence- and structure-based immunoreactive epitope discovery for Burkholderia pseudomallei flagellin","volume":"9","author":"Nithichanon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0275","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/febs.13223","article-title":"From crystal structure to in silico epitope discovery in the Burkholderia pseudomallei flagellar hook-associated protein FlgK","volume":"282","author":"Gourlay","year":"2015","journal-title":"FEBS J"},{"key":"10.1016\/j.vaccine.2017.03.022_b0280","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/cb500831y","article-title":"Structure-based design of a B cell antigen from B. pseudomallei","volume":"10","author":"Gaudesi","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0285","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.chembiol.2013.07.010","article-title":"Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery\/design in structural vaccinology","volume":"20","author":"Gourlay","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0290","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1128\/IAI.74.3.1699-1705.2006","article-title":"CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB\/c mice","volume":"74","author":"Chen","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0295","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.vaccine.2005.08.069","article-title":"Immunogenicity and anti-Burkholderia pseudomallei activity in Balb\/c mice immunized with plasmid DNA encoding flagellin","volume":"24","author":"Chen","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0300","doi-asserted-by":"crossref","first-page":"e1453","DOI":"10.1371\/journal.pntd.0001453","article-title":"The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide","volume":"6","author":"Tuanyok","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0305","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.carres.2013.08.013","article-title":"Revised structures for the predominant O-polysaccharides expressed by Burkholderia pseudomallei and Burkholderia mallei","volume":"381","author":"Heiss","year":"2013","journal-title":"Carbohyd Res"},{"key":"10.1016\/j.vaccine.2017.03.022_b0310","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/gb-2010-11-8-r89","article-title":"Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates","volume":"11","author":"Sim","year":"2010","journal-title":"Genome Biol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0315","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1099\/jmm.0.45766-0","article-title":"Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis","volume":"53","author":"Nelson","year":"2004","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0320","doi-asserted-by":"crossref","first-page":"392170","DOI":"10.1155\/2014\/392170","article-title":"Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate","volume":"2014","author":"Scott","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.vaccine.2017.03.022_b0325","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1099\/0022-1317-51-12-1055","article-title":"Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins","volume":"51","author":"Jones","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0330","unstructured":"Anon. Select agents and toxins exclusions. Attenuated strains of overlap select agents excluded from the requirements of 9 CFR Part 121 and 42 CFR part 73: federal select agent program: centers for disease control and prevention and animal and plant health inspection service; 2014."},{"key":"10.1016\/j.vaccine.2017.03.022_b0335","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1016\/j.vaccine.2010.08.058","article-title":"Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis","volume":"28","author":"Ngugi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0340","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nano.2014.08.005","article-title":"A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei","volume":"11","author":"Gregory","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0345","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2014.11.057","article-title":"Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine","volume":"33","author":"Torres","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0350","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/acs.bioconjchem.5b00525","article-title":"Protection against experimental melioidosis with a synthetic manno-heptopyranose hexasaccharide glycoconjugate","volume":"27","author":"Scott","year":"2016","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.vaccine.2017.03.022_b0355","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1021\/acschembio.5b00502","article-title":"Burkholderia pseudomallei capsular polysaccharide recognition by a monoclonal antibody reveals key details toward a biodefense vaccine and diagnostics against melioidosis","volume":"10","author":"Marchetti","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0360","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/IAI.01847-14","article-title":"Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis","volume":"82","author":"Scott","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0365","first-page":"108","article-title":"Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders","volume":"2","author":"Burtnick","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0370","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1155\/1994\/856850","article-title":"Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei","volume":"5","author":"Bryan","year":"1994","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0375","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/IAI.64.7.2824-2828.1996","article-title":"Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates","volume":"64","author":"Brett","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0380","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fmicb.2014.00381","article-title":"Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery","volume":"5","author":"Garcia-Quintanilla","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0385","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.drudis.2008.04.010","article-title":"Vaccines against intracellular bacterial pathogens","volume":"13","author":"Titball","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2017.03.022_b0390","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA animal rule","volume":"1","author":"Beasley","year":"2016","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2017.03.022_b0395","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/iep.12161","article-title":"Characterization of lesion formation in marmosets following inhalational challenge with different strains of Burkholderia pseudomallei","volume":"96","author":"Nelson","year":"2015","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0400","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1128\/IAI.00675-12","article-title":"Natural history of inhalation melioidosis in rhesus macaques (Macaca mulatta) and African green monkeys (Chlorocebus aethiops)","volume":"80","author":"Yeager","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1099\/jmm.0.059063-0","article-title":"Pathological findings and diagnostic implications of a rhesus macaque (Macaca mulatta) model of aerosol-exposure melioidosis (Burkholderia pseudomallei)","volume":"63","author":"Yingst","year":"2014","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0410","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1099\/jmm.0.000065","article-title":"Pathological findings and diagnostic implications of a rhesus macaque (Macacca mulatta) model of aerosol exposure to Burkholderia mallei (glanders)","volume":"64","author":"Yingst","year":"2015","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0415","doi-asserted-by":"crossref","first-page":"e0124181","DOI":"10.1371\/journal.pone.0124181","article-title":"Use of the common marmoset to study Burkholderia mallei infection","volume":"10","author":"Jelesijevic","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.022_b0420","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/iep.12105","article-title":"Comparative experimental subcutaneous glanders and melioidosis in the common marmoset (Callithrix jacchus)","volume":"95","author":"Nelson","year":"2014","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0425","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0430","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.vaccine.2012.05.049","article-title":"Immune markers and correlates of protection for vaccine induced immune responses","volume":"30","author":"Thakur","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0435","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/fmb.16.15","article-title":"Human biomarkers: can they help us to develop a new tuberculosis vaccine?","volume":"11","author":"Fletcher","year":"2016","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0440","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tube.2016.08.001","article-title":"Antibodies and tuberculosis","volume":"101","author":"Jacobs","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0445","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7883\/yoken.67.436","article-title":"Effect of host factors on neutrophil functions in response to Burkholderia pseudomallei in healthy Thai subjects","volume":"67","author":"Saengmuang","year":"2014","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0450","doi-asserted-by":"crossref","first-page":"34794","DOI":"10.1038\/srep34794","article-title":"Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione","volume":"6","author":"Kewcharoenwong","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.03.022_b0455","doi-asserted-by":"crossref","first-page":"e2988","DOI":"10.1371\/journal.pntd.0002988","article-title":"Delineating the importance of serum opsonins and the bacterial capsule in affecting the uptake and killing of Burkholderia pseudomallei by murine neutrophils and macrophages","volume":"8","author":"Mulye","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0460","doi-asserted-by":"crossref","first-page":"e90930","DOI":"10.1371\/journal.pone.0090930","article-title":"Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei","volume":"9","author":"Peddayelachagiri","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.022_b0465","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/498983","article-title":"Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection","volume":"193","author":"Haque","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0470","article-title":"Burkholderia pseudomallei proteins presented by monocyte-derived dendritic cells stimulate human memory T-cells in vitro","volume":"1","author":"Tippayawat","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0475","doi-asserted-by":"crossref","first-page":"e0004152","DOI":"10.1371\/journal.pntd.0004152","article-title":"T-cell responses are associated with survival in acute melioidosis patients","volume":"9","author":"Jenjaroen","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.03.022_b0480","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4049\/jimmunol.166.2.1097","article-title":"Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens","volume":"166","author":"Lertmemongkolchai","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0485","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1128\/IAI.01384-08","article-title":"Protection from pneumonic infection with Burkholderia species by inhalational immunotherapy","volume":"77","author":"Goodyear","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0490","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2016.07.058","article-title":"In vitro mycobacterial growth inhibition assays: a tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy","volume":"34","author":"Tanner","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0495","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1016\/j.vaccine.2016.09.002","article-title":"Polyfunctional CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants","volume":"34","author":"Smith","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0500","doi-asserted-by":"crossref","first-page":"e0138042","DOI":"10.1371\/journal.pone.0138042","article-title":"Intracellular cytokine staining and flow cytometry: considerations for application in clinical trials of novel tuberculosis vaccines","volume":"10","author":"Smith","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.022_b0505","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1016\/j.vaccine.2015.03.072","article-title":"Systems vaccinology: enabling rational vaccine design with systems biological approaches","volume":"33","author":"Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0510","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20151960","article-title":"Reverse vaccinology 2.0: human immunology instructs vaccine antigen design","volume":"213","author":"Rappuoli","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.03.022_b0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3642","article-title":"Democratizing systems immunology with modular transcriptional repertoire analyses","volume":"14","author":"Chaussabel","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0520","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0525","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/gb-2009-10-11-r127","article-title":"Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis","volume":"10","author":"Pankla","year":"2009","journal-title":"Genome Biol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0530","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.4049\/jimmunol.1500641","article-title":"The blood transcriptome of experimental melioidosis reflects disease severity and shows considerable similarity with the human disease","volume":"195","author":"Conejero","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.03.022_b0535","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1128\/IAI.00404-07","article-title":"Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis","volume":"75","author":"Harland","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.03.022_b0540","doi-asserted-by":"crossref","first-page":"e6496","DOI":"10.1371\/journal.pone.0006496","article-title":"Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets","volume":"4","author":"Hara","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.03.022_b0545","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1016\/j.vaccine.2010.05.022","article-title":"Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice","volume":"28","author":"Su","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0550","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1016\/j.vaccine.2007.08.045","article-title":"Analysis of peptide mimotopes of Burkholderia pseudomallei exopolysaccharide","volume":"25","author":"Legutki","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.03.022_b0555","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.vaccine.2016.03.088","article-title":"Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis","volume":"34","author":"Casey","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17303286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T05:04:54Z","timestamp":1601787894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17303286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":111,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17303286"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}